BC
JANX icon

Bridgefront Capital’s Janux Therapeutics JANX Stock Holding History

Bridgefront Capital’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,692
Closed -$274K – 640
2026
Q1 		$274K Buy
+19,692
New +$270K 0.07% 413

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Bridgefront Capital's JANX Position: Q2 2026 in Review

Bridgefront Capital sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 19,692 shares — an estimated $274K sold.

Bridgefront Capital first reported a position in JANX in Q1 2026 and held it in 1 quarter. The position peaked at $274K in Q1 2026. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Bridgefront Capital reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bridgefront Capital sold 19,692 Janux Therapeutics shares in Q2 2026, an estimated $274K.
  • Bridgefront Capital first reported a position in Janux Therapeutics in Q1 2026 and held it in 1 quarter.
  • Bridgefront Capital's Janux Therapeutics position peaked at $274K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.